Although the analysis of the biomarkers for oxidative stress (FoxO1 and SOD2) provided reasonable and consistent positive results, validating the fundamental role of this event in contributing to CCM disease pathogenesis [13,16], this study needs further improvements to the analysis of these two sets of therapeutic targets. The gene discussed is FOXO1; the disease is cerebral cavernous malformation.